Pages that link to "Q52117074"

The following pages link to A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. (Q52117074):

Displaying 45 items.

• Polyunsaturated fatty acid supplementation for schizophrenia (Q24245513) (← links)
• Miscellaneous treatments for neuroleptic-induced tardive dyskinesia (Q24248650) (← links)
• Polyunsaturated fatty acid supplementation for schizophrenia (Q24248708) (← links)
• Implications of lipid biology for the pathogenesis of schizophrenia (Q30697695) (← links)
• Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia (Q33179595) (← links)
• Bioactive lipids in schizophrenia (Q33246888) (← links)
• Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder (Q33964656) (← links)
• Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia (Q34259921) (← links)
• Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications (Q34313506) (← links)
• Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects (Q34465150) (← links)
• Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia (Q34515196) (← links)
• Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations (Q34583573) (← links)
• A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E). (Q35012774) (← links)
• Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications (Q35102465) (← links)
• From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? (Q35586753) (← links)
• Drug interactions between herbal and prescription medicines. (Q35593896) (← links)
• Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia (Q36508050) (← links)
• Tardive dyskinesia and essential fatty acids (Q36508056) (← links)
• Huntington's disease: pathological mechanisms and therapeutic strategies (Q36822322) (← links)
• Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain (Q37833540) (← links)
• Environmental factors and membrane polyunsaturated fatty acids in schizophrenia (Q40548904) (← links)
• Free radical pathology in schizophrenia: a review (Q41185166) (← links)
• Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation (Q41185182) (← links)
• Antioxidant treatment of tardive dyskinesia (Q41185188) (← links)
• Dyskinesias and their treatment with essential fatty acids: a review (Q41185198) (← links)
• Heat stress lipids and schizophrenia (Q41185226) (← links)
• Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites (Q42526777) (← links)
• Update and critique of natural remedies as antidepressant treatments (Q42690784) (← links)
• A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms (Q43832862) (← links)
• Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients (Q44270021) (← links)
• On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis (Q44589854) (← links)
• Essential fatty acid-rich diets protect against striatal oxidative damage induced by quinolinic acid in rats. (Q45293662) (← links)
• Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease (Q45305057) (← links)
• Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia (Q46882666) (← links)
• Essential fatty acids and mental illness (Q48495504) (← links)
• High levels of dietary arachidonic acid triglyceride exhibit no subchronic toxicity in rats (Q48744414) (← links)
• Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls (Q48946848) (← links)
• Natural Medicines for Psychotic Disorders: A Systematic Review. (Q49363880) (← links)
• Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia (Q51666183) (← links)
• Essential Fatty Acids in Alzheimer's Diseasea (Q53182004) (← links)
• Miscellaneous treatments for antipsychotic-induced tardive dyskinesia (Q57689401) (← links)
• Miscellaneous treatments for neuroleptic-induced tardive dyskinesia (Q57692273) (← links)
• Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients (Q71719467) (← links)
• Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933 (Q71719471) (← links)
• Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients (Q73521181) (← links)